Half-Year 2022 Financial and Clinical Trials Update

2022 outlook Group sales growth1 Core EPS growth¹ • Stable to low-single digit • Dividend outlook • 1 At Constant Exchange Rates (CER) Low- to mid-single digit Further increase dividend in Swiss francs Roche 70

View entire presentation